Immunity to murine sarcoma virus induced tumours. IV. Direct cellular cytolysis of 51Cr labelled target cells in vitro and analysis of blocking factors which modulate cytotoxicity

Mechanisms of tumor evasion from the immune response

The results from in vitro immunological experiments, murine tumor models and patients with cancer clearly demonstrate that tumors have multiple mechanisms to evade the immune response. During the early stages of tumor development malignant cells can be poor stimulators, present poor targets or become resistant to the innate immune response, while at later stages, progressively growing tumors impair the adaptive immune response by blocking the maturation and function of APCs and causing alterations in T-cell signal transduction and function. Preliminary results also suggest a correlation between some of these changes and an increased metastatic potential of the tumor cells, a diminished response to immunotherapy, and poor prognosis. Carefully coordinated basic research studies and clinical immunotherapy trials will be required to fully determine the impact of these mechanisms of tumor evasion on the outcome of the disease and the response to treatment. However, understanding the mechanisms used by tumor cells to evade the immune system could result in new therapeutic approaches for preventing and/or reversing these immune alterations and could have the potential of improving the current results of immunotherapy trials.

Suppressor mechanisms in tumor immunity

There are many parallels between T cell-mediated suppression of tumor immunity and suppression of immune responses to haptens and polypeptides. We propose a cell interaction model which takes this into account and outlines a regulatory pathway for suppression of immunity to tumor antigens. Free antigen or antigen/antibody complexes trigger an inducer T cell subset, Tsi, which is tumor-specific. This cell activates a non-immune T cell population, pre Tse, to generate effector suppressor cells, Tse. The Tse are specific for either the idiotype of Tsi or for antigen complexed with a soluble factor made by the Tsi, but the suppression they mediate is antigenically nonspecific. Tumor antigen-specific suppressor factors, TsF, play a major role in the communication between different suppressor cells. Characterization of polyclonal and monoclonal factors produced by Tsi, called TsFi, indicates that they both bind to tumor antigen and contain tumor-specific (idiotypic?) determinants.

Genetic control of sensitivity to moloney leukemia virus in mice. VI. Involvement of virus-specific T helper cells collaborating with B cells

T cell responses to Moloney virus involve cytolytic and helper lymphocytes. In contrast to specific cytolytic T lymphocytes, few studies have been devoted to the characteristics of helper T cells for antibody production. The present experiments describe an assay for Moloney virus-specific help for B cells using dinitrophenylated virus. This method, using the Moloney virus as a carrier in a hapten-carrier system, allows to definition of the specific helper function of antibody responses. T helper cells were induced in murine sarcoma virus or inactivated Moloney murine leukemia virus-primed spleens or lymph nodes. T helper function was due to Thy-1.2, Lyt-1+2- cells and was macrophage-dependent. It was stimulated by whole virus of Moloney gp71 envelope protein but not Moloney p30 internal protein. Cross-reactive stimuli were obtained with other dinitrophenylated type C viruses. High and low responses were correlated respectively with resistance and susceptibility to Moloney leukemia virus. Cultures of helper T cells with preserved activity have been established and maintained for one month.

Anti-tumor immunity in B-lymphocyte-deprived mice. III. Immunity to primary Moloney sarcoma virus-induced tumors

Tumor induction and immunity to tumors were studied following the injection of Moloney sarcoma virus (MSV) into mice whose B-lymphocyte functions had been suppressed by the chronic administration of anti-IgM antibodies. Two preparations of MSV were used; one which gives rise to tumors which uniformly regress in normal adult mice, and another which elicits progressively growing tumors in the majority of recipients. The tumor incidence, mean tumor size, and tempo of regression were not modified by treatment with anti-IgM. However, whereas tumors induced by the regressor virus were all rejected in 19 NRG-treated and 29 untreated recipients, continued growth was obtained in 2 of 23 B-lymphocyte-deprived mice. Furthermore, in 9 additional mice from this group, apparent rejection was followed by tumor recurrence at the site of the initial tumor. Continued growth was accompanied by widespread metastasis. These tumors were freely transplantable to normal syngeneic recipients. Metastasis and transplantability were also detected in 7 of 24 anti-IgM-treated mice given progressor virus, but were not seen in the control animals. Recurrence and metastasis was obtained despite the presence of high levels of specific cytotoxic T lymphocytes in the spleen. It is concluded that B lymphocytes or their products play an essential role in host protection against MSV-induced tumors.

Inhibition of cell proliferation rather than of cell lysis as a measure of immune reactivity in embryo-antigen-challenged mice

An assay system is described in which effector cells added along with suitable target cells inhibit, in a quantitative fashion, the subsequent uptake of 3H-thymidine by those target cells. Effector cells active in this assay, using embryonic fibroblast cells as targets, develop spontaneously in cultures of mouse lymphoid cells, but are apparently different from those described earlier by investigators of activity in cytotoxic assays. Further evidence is presented to show the development of spleen-derived effector cells with cytostatic activity (for embryonic fibroblast target cells) in mice during the course of normal pregnancy, or growth of spontaneously appearing mammary adenocarcinomas. Indeed, such effector cells can also be found within the growing solid mass itself. Different populations of tumour cells isolated from a solid tumour apparently differ in their susceptibility to growth inhibition by tumour-bearer-derived cytostatic effector cells, a phenomenon which may be related to metastatic spread of tumour cells.

Guinea pig cell-mediated tumor immunity: the chromium release assay detects both cytolysis and serum blocking for syngeneic chemically-induced tumors

The chromium release test (CRT) was used to assess cell-mediated immunity to syngeneic, chemically-induced tumors in guinea pigs. The animal models were Sewall Wright strain 13 guinea pigs with 3-methyl-cholanthrene (MCA)-induced fibrosarcomas and strain 2 guinea pigs with diethylnitrosamine (DEN)-induced hepatocarcinomas. Regional lymph node cells were significantly cytolytic for the immunizing tumors, specifically so for three of the four tumors, and tumor-bearer sera could significantly block cytolysis. The two DEN-induced strain 2 hepatomas, line 1 and line 10, are antigenically distinct by the CRT but the two MCA-induced tumors have tumor specific antigens as well as a common, cross-reactive antigen.

Lymphocyte cytotoxicity in the X-irradiation induced rat small bowel adenocarcinoma. II. Presence of cytotoxic lymphocytes in irradiated animals

Cytotoxic peripheral blood lymphoid cells were demonstrated in both Holtzman and Lewis Brown-Norway rats which had received 2000R of local X-irradiation to the temporarily hypoxic, exteriorized, ileum and jejunum regardless of whether a small bowel adenocarcinoma subsequently developed. The cytotoxic response, which was detectable at two days, was quite evident by day 5 post-irradiation. No evidence of cross-reacting tumor antigens was obtained when similarly processed effector cells from Holtzman rats bearing a spontaneous mammary carcinoma were incubated with cell cultures derived from the small bowel adenocarcinoma. These findings indicate X-irradiation of the small bowel initiates lymphocyte sensitization that is manifested as in vitro cytotoxicity against cell cultures of the adenocarcinoma.

Murine sarcoma virus (MSV)-induced tumors in mice. I. Distribution of MSV-immune cytolytic T lymphocytes in vivo

Quantitative studies using a 51Cr release assay were performed to analyse the time-course of appearance and specificity of cytolytic cells in C57Bl/6 mice inoculated with Moloney murine sarcoma virus (MSV). Various lymphoid organs were studied including spleen, mesenteric lymph nodes (MLN), lymph nodes regional to the MSV-induced tumor (RLN), and peripheral blood. Furthermore, the kinetics of appearance of cytolytic cells within the MSV-induced tumor was determined. In agreement with previous studied, it was found that cytolytic T lymphocytes (CTL) specific for MSV-associated antigens were present among the cells extracted from the tumor and from the lymphoid organs. However, differences in the kinetics of CTL activity could be documented: lymphoid cells from spleen, RLN and peripheral blood showed peak activity at the time of maximum tumor diameter, while intratumoral cells showed peak activity at the onset of tumor regression. MLN cells showed cytolytic activity only when tumor regression had begun. Naturally cytotoxic cell populations of thymus-independent origin, present in normal control mice, were also detected in MSV-infected mice.

Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells

Incubation of spleen cells from mice having rejected a Moloney sarcoma virus (MSV)-induced tumor with syngeneic irradiated lymphoma or sarcoma cells bearing MSV-associated antigens in secondary mixed leukocyte-tumor cell cultures (MLTC) resulted in the generation of highly active cytolytic T lymphocytes (CTL) specifically directed against syngeneic target cells bearing MSV-associated antigens. When MSV-immune spleen cells from C57BL/6 (H-2b) and BALB/c(H-2d) mice were compared with respect to their ability to generate CTL in syngeneic secondary MLTC, it was found that both lymphoid cell populations were equally able to mount an anamnestic CTL response to MSV-associated antigens as assessed by a short-term 21Cr release assay. However, quantitative analysis of the activity of both CTL populations on either H-2b or H-2d tumor cells indicated that target cells sharing the same major histocompatibility complex (MHC) as the effector cells were lysed 10- to 100-fold more efficiently than allogeneic target cells. As suggested by the results of inhibition experiments using mixtures of 51Cr-labeled and unlabeled target cells, preferential lysis of syngeneic versus allogeneic tumor cells might be related to the establishment of effective adhesions between the former and CTL. Direct evidence for the role of MHC in determining the antigenic specificity of CTL directed against MSV-associated antigens was provided by results obtained using MSV-immune spleen cells from congenic resistant mice. Furthermore, studies of the response of F1 (H-2b/d) hybrid mice showed that stimulation of immune spleen cells with tumor cells from one parental strain or the other in secondary MLTC resulted in the generation of CTL capable of lysing tumor target cells of the same perental strain as the stimulating cells, but not of the other. The results thus suggested the presence of two sets of CTL precursor cells in F1 MSV-immune spleens, each set responding exclusively to tumor antigens associated with only one of the two parental phenotypes.

Autoreactivity developing spontaneously in cultured mouse spleen cells. I. Evidence that cytotoxicity is directed against embryo-associated antigen

We have investigated the ability of male-mouse spleen cells before and after culture in the absence of deliberate antigenic stimulation to show specific cytotoxicity to syngeneic embryo-fibroblast cells. The data suggest that cytotoxicity which develops spontaneously in such spleen cell cultures is directed primarily against embryo-associated antigens. Syngeneic Con-A-stimulated spleen cells, which, unlike fresh normal spleen cells, are also lysed by rabbit anti-mouse embryo antisera, are also a suitable target to demonstrate spontaneously developing cytotoxicity.

Cell-mediated immunity to mouse tumors: some recent findings

Lymphocyte mediated immune reactions play a major role in the immunological defense against antigenic tumor cells. Serum factors (antigens, antigen-antibody complexes) can thwart these reactions, perhaps by interfering with a lymphocyte "activation" process. Blocking factors can be eluted from lymphoid cells harvested from tumor-bearing animals. One way of increasing cell-mediated reactivity to tumor antigens appears to be to sensitize (or "activate") lymphocytes against tumor antigens in vitro. Another way may be to inoculate animals with sera containing lymphocyte-dependent and unblocking antibodies. Preliminary evidence is presented that inoculation of such sera from rabbits immunized with mouse embryonie cells and extensively absorbed may delay the appearance of primary, methyleholanthrene-induced sarcomas in BALB/c mice; the mechanisms responsible for this delay remain unknown.

The effect of cyclophosphamide and irradiation on cells which suppress contact sensitivity in the mouse

Contact sensitivity was produced in mice by painting the skin with picryl chloride and was assessed by the increase in ear thickness following local challenge. Contact sensitivity was passively transferred by immune lymph node and spleen cells taken at 4 days. The mice were then challenged immediately and the reactions read at 24 and 48 hr. Immune lymph node and spleen cells taken at day 8 virtually fail to transfer. Experiment showed that they contain cells which suppress passive transfer. These are demonstrated by mixing approximately equal numbers of 4-day cells, which transfer contact sensitivity, and cells taken at later times and injecting them intravenously into recipients. These 'suppressor cells' can be demonstrated by day 6 and are still present at day 11 after immunization. The precursors of the suppressor cells are sensitive to cyclophosphamide. Irradiation of immune mice 2 days before taking cells also selectively inactivates the suppressor cells. When mice are pretreated with cyclophosphamide before immunization or irradiated 2 days before transfer, the lymph node and spleen cells taken on day 9 after immunization transfer contact sensitivity. In contrast the same number of cells from untreated mice were inactive. This suggests that the cells which mediate passive transfer or their precursors may occur in an inhibited form in lymph nodes and spleen at later times after immunization. These suppressor cells in immune mice differ from the T suppressor cells produced by the injection of picryl sulphonic acid--an agent which causes unresponsiveness: (1) the precursors of the T suppressor cells resist cyclophosphamide; (2) the T suppressor cells are found in mice treated so as to produce unresponsiveness while the other type of suppressor cells occurs in mice immunized for contact sensitivity. However, both types of suppressor cells are selectively inactivated by irradiation as compared with the cells which mediate contact sensitivity and both are able to act on the effector stage of contact sensitivity.

Antigenic specificities of the cell-mediated anti-tumor reactions in the MSV system studied by the secondary chromium release test

The SCRT and the inhibition test have been used to determine the specificity of cell surfacr antigens reacting with anti-M-MSV cytolytic lymphocytes. The method provides very sensitive and specific results. Some discrepancies exist between the results of SCRT and those obtained by the in vitro inhibition by tumor cells of cell-mediated immune cytolysis. The main point is that allogeneic cells are stimulatory in SCRT, whereas they are not reactive in the inhibition test. Several hypotheses are discussed to explain these discrepancies. In all the experiments, a strong secondary stimulation of cytotoxic lymphocytes was obtained in vitro when FMRGi (+) cells were used as stimulators, whatever the nature and the histocompatibility antigens of these cells. This suggests that an antigen of the "FMRGi system" is regularly involved in the cell-mediated anti-MSV reaction. However, other antigenic specificities of different natures are probably also concerned due to the antigenic complexity of these tumors.

Studies on mouse Moloney virus induced tumours: I. The detection of p30 as a cytotoxic target on murine Moloney leukaemic spleen cells, and on an in vitro Moloney sarcoma line by antibody mediated cytotoxicity

Antigenic determinants of p30, the most abundant internal virion protein of C type RNA viruses, were detected on the surface of spleen cells from mice bearing Moloney leukaemia and on an in vitro line of Moloney sarcoma, MSC. On both cell types, these determinants on the p30 molecules served as cytotoxic targets in a xenogenic complement dependent antibody mediated 51Cr release assay. Two antisera were used: a rat anti MLV -M induced lymphoma serum, and an antiserum raised in goats to either disrupted FeLV. The cytotoxic target antigens of these antisera were analysed by inhibition of cytotoxicity with viral and cellular proteins.